Literature DB >> 12074215

Tadalafil (Cialis) for men with erectile dysfunction.

I Eardley1, J Cartledge.   

Abstract

Tadalafil is an inhibitor of phosphodiesterase type 5, and is currently undergoing regulatory review in the US and in Europe. Its chemical structure is significantly different from sildenafil, and in vitro studies confirm significant potency for PDE5 inhibition, with little activity against most of the other isoforms of the enzyme including PDE6, which is the isoform of the enzyme found within the retina. The half-life of tadalafil is 17.5 hours and clinical studies suggest significant activity 24 hours post-dosing. As with sildenafil, efficacy depends upon a normal sexual stimulus, and the drug can taken be as required. Tadalafil is effective in the treatment of men with erectile dysfunction, and it appears to have a relatively mild side-effect profile, with no visual side-effects noted.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12074215

Source DB:  PubMed          Journal:  Int J Clin Pract        ISSN: 1368-5031            Impact factor:   2.503


  21 in total

1.  PDE5 is converted to an activated state upon cGMP binding to the GAF A domain.

Authors:  Sergei D Rybalkin; Irina G Rybalkina; Masami Shimizu-Albergine; Xiao-Bo Tang; Joseph A Beavo
Journal:  EMBO J       Date:  2003-02-03       Impact factor: 11.598

2.  Inhibitors of phosphodiesterase 5 (PDE 5) inhibit the nerve-induced release of nitric oxide from the rabbit corpus cavernosum.

Authors:  K Hallén; N P Wiklund; L E Gustafsson
Journal:  Br J Pharmacol       Date:  2006-12-18       Impact factor: 8.739

3.  Cyclic AMP-specific and cyclic GMP-specific phosphodiesterase isoenzymes in human cavernous arteries--immunohistochemical distribution and functional significance.

Authors:  Eginhard Waldkirch; Stefan Uckert; Hüseyin Yildirim; Michael Sohn; Udo Jonas; Christian G Stief; Karl-Erik Andersson; Petter Hedlund
Journal:  World J Urol       Date:  2005-11-15       Impact factor: 4.226

Review 4.  Evidence for the efficacy and safety of tadalafil and finasteride in combination for the treatment of lower urinary tract symptoms and erectile dysfunction in men with benign prostatic hyperplasia.

Authors:  Chris Olesovsky; Anil Kapoor
Journal:  Ther Adv Urol       Date:  2016-05-26

5.  Cardiovascular protection with sildenafil following chronic inhibition of nitric oxide synthase.

Authors:  R C Kukreja
Journal:  Br J Pharmacol       Date:  2007-01-22       Impact factor: 8.739

Review 6.  Etiology and treatment of erectile failure in diabetes mellitus.

Authors:  Donald Richardson; Aaron Vinik
Journal:  Curr Diab Rep       Date:  2002-12       Impact factor: 4.810

Review 7.  [The basics of phosphodiesterase type 5 (PDE5) inhibition in urology].

Authors:  A J Becker; S Uckert; C G Stief
Journal:  Urologe A       Date:  2008-12       Impact factor: 0.639

8.  Efficacy and Safety of Tadalafil 5 mg Administered Once Daily in Korean Men with Erectile Dysfunction: A Prospective, Multicenter Study.

Authors:  Dong Hyuk Kang; Joo Yong Lee; Sung Yul Park; Hong Sang Moon; Tae Yoong Jeong; Tag Keun Yoo; Hong Yong Choi; Hae Young Park; Tchun Yong Lee; Seung Wook Lee
Journal:  Korean J Urol       Date:  2010-09-17

9.  Comparison of the efficacy and safety of 5-mg once-daily versus 5-mg alternate-day tadalafil in men with erectile dysfunction and lower urinary tract symptoms.

Authors:  H Choi; J-H Kim; J-S Shim; J Y Park; S H Kang; D G Moon; J Cheon; J G Lee; J J Kim; J-H Bae
Journal:  Int J Impot Res       Date:  2014-07-03       Impact factor: 2.896

Review 10.  Current use of phosphodiesterase inhibitors in urology.

Authors:  Tariq Said Hakky; Lakshay Jain
Journal:  Turk J Urol       Date:  2015-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.